Stay
Engaged
![](http://cerecin.new-mentus.com/wp-content/themes/cerecin/i/hero-second-half.png)
News & Publications
News & Publications
News
07 December 2022
Cerecin received US FDA clearance to study CER-0001 under an Investigational New Drug (IND) application for Infantile Spasms
25 November 2022
Poster presentation on the Metabolic Mechanism in Migraine: Tricaprilin, a Ketogenic Agent
17 November 2022
Cerecin appoints Mr. Brian Young-Hoon Kim as new Head of Investor Relations
![decorative molecules](http://cerecin.new-mentus.com/wp-content/themes/cerecin/i/molecules-left.png)
![decorative molecules](http://cerecin.new-mentus.com/wp-content/themes/cerecin/i/molecules-right.png)
Publications
Application of FibroScan for hepatic safety monitoring in early clinical studies
Sabina Paglialunga, PhD, Terry O’Reilly, MD CPI, Samuel Henderson, PhD, Bruce H Morimoto, PhD, Lilian Chow, MRDM, Nor Rahimah binte Ramli, Lars Nelleman, MD, Judith Walker, MD 2021 ACCP Virtual Annual Meeting
Administering tricaprilin after a meal optimises bioavailability and minimises adverse events
Judith Anne Walker, MD; Lars Nelleman,MD; Lilian Chow, MRDM; Bruce Morimoto, PhD Clinical Trials on Alzheimer’s Disease 2020
Tricaprilin shows similar PK, safety and tolerability in Caucasians and Chinese
Bruce H. Morimoto, PhD; Lilian Chow, MRDM; Lars Nelleman,MD; Judith Anne Walker, MD Clinical Trials on Alzheimer’s Disease 2020
![decorative molecules](http://cerecin.new-mentus.com/wp-content/themes/cerecin/i/molecules-left.png)
Events
9–12
November
2021
Clinical Trials on Alzheimer's Disease conference (CTAD)
19–23
October
2021
7th Global Symposium on medical ketogenic dietary therapies
8 – 12
September
2021